Document is current

Article History

Received: 24 November 2025

Accepted: 31 January 2026

First Online: 25 February 2026

Declarations

:

: Authors VD, VL, LD, TB are employed by Inovatyvi medicina UAB. Authors VD, VL, TB hold shares in Inovatyvi medicina UAB. CZ has served as a consultant and has received research support, honoraria, and travel support from W.L. Gore & Associates, LeMaitre Vascular, Atrium Maquet Getinge Group, Artivion, and Terumo (Vascutek and Bolton). LP has served as a consultant and received honoraria and travel support from Inovatyvi medicina UAB, Abbott, Angiodroid, Asahi, Bentley, Biotronik, COOK, Shockwave, Terumo. GFT has served as a consultant and received honoraria and travel support from Balt, Boston Scientific, Cook, iVascular, Medtronic, Penumbra, Terumo. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. The study was conducted in compliance with ISO 10993–2, GLP standards, and under the Quality Management System of the testing facility. Ethical approval was obtained from the Animal Care and Use Committee of the Testing Facility, which was registered with the CNREEA under the Ethics Committee No. 37. The study was part of research project ROBOTIQUE 42515. The program of the Testing Facility conforms with AAALAC International standards as set by the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (Council of Europe ETS 123), French implementing legislation, and the Guide for the Care and Use of Laboratory Animals (NRC 2011).